CorMedix Inc. (CRMD)
NASDAQ: CRMD · IEX Real-Time Price · USD
5.71
-0.13 (-2.31%)
At close: May 8, 2024, 4:00 PM
5.85
+0.14 (2.54%)
After-hours: May 8, 2024, 6:28 PM EDT
CorMedix Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CorMedix stock have an average target of 13, with a low estimate of 9.00 and a high estimate of 19. The average target predicts an increase of 127.87% from the current stock price of 5.71.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CorMedix stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $19 | Buy | Reiterates | $19 | +233.04% | Apr 9, 2024 |
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +75.28% | Apr 9, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +57.76% | Mar 13, 2024 |
| Needham | Needham | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +75.28% | Mar 12, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +145.40% | Jan 31, 2024 |
Financial Forecast
Revenue This Year
25.66M
Revenue Next Year
83.56M
from 25.66M
Increased by 225.63%
EPS This Year
-0.76
from -0.91
EPS Next Year
-0.10
from -0.76
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 48.7M | 111.0M | 194.2M | 304.7M | 387.9M |
| Avg | 25.7M | 83.6M | 165.2M | 256.9M | 336.1M |
| Low | 14.3M | 65.6M | 136.2M | 209.3M | 283.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 332.7% | 132.4% | 84.4% | 50.9% |
| Avg | - | 225.6% | 97.7% | 55.5% | 30.8% |
| Low | - | 155.7% | 63.0% | 26.7% | 10.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.27 | 0.58 | 1.70 | 3.18 | 4.25 |
| Avg | -0.76 | -0.10 | 1.17 | 2.35 | 3.14 |
| Low | -1.07 | -0.66 | 0.67 | 1.55 | 2.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 171.2% | 80.9% |
| Avg | - | - | - | 100.4% | 33.4% |
| Low | - | - | - | 32.0% | -12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.